These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18271940)

  • 1. Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
    Sasaki K; Yamagata T; Mitani K
    Cancer Sci; 2008 Feb; 99(2):414-22. PubMed ID: 18271940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
    Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
    J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.
    Maki K; Sugita F; Nakamura Y; Sasaki K; Mitani K
    Int J Hematol; 2013 Jan; 97(1):83-91. PubMed ID: 23250858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
    Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
    Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
    Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
    J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
    Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
    Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors promote osteoblast maturation.
    Schroeder TM; Westendorf JJ
    J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells.
    Starkova J; Madzo J; Cario G; Kalina T; Ford A; Zaliova M; Hrusak O; Trka J
    Clin Cancer Res; 2007 Mar; 13(6):1726-35. PubMed ID: 17325341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
    Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
    Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
    Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
    Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
    Amann JM; Nip J; Strom DK; Lutterbach B; Harada H; Lenny N; Downing JR; Meyers S; Hiebert SW
    Mol Cell Biol; 2001 Oct; 21(19):6470-83. PubMed ID: 11533236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU
    Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
    Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
    Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
    Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
    Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
    Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
    Zhu J; Gu J; Ma J; Xu Z; Tao H
    J BUON; 2015; 20(1):269-74. PubMed ID: 25778327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.